君实生物：昂戈瑞西单抗注射液新适应症上市申请获得批准

Core Viewpoint - Junshi Biosciences has received approval from the National Medical Products Administration for the new indication of its drug, Oncorhynchus monoclonal antibody injection (brand name: Junshida®), for treating adult patients with heterozygous familial hypercholesterolemia (HeFH) and those intolerant to statins or contraindicated for statin use [1] Company Summary - Junshi Biosciences' Oncorhynchus monoclonal antibody injection is now the first domestically approved PCSK9-targeted drug for patients intolerant to statins [1]